https://doi.org/10.4081/hmr.v3i3.553

Blastic plasmacytoid dendritic cell neoplasm

Vol. 3 No. 3: 7th Meeting New Insights in Hematology Venice, Italy, 26-29 April 2009
Published: June 12, 2009
Abstract Views: 4729
PDF: 4046
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

F Facchetti
support@pagepress.org
M Ungari
D Marocolo
S Lonardi
W Vermi
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare haematological malignancy characterized by the clonal proliferation of immature or precursors of plasmacytoid dendritic cells (PDC), also known as professional type I interferon producing cells.1 This neoplasm was originally recognized in 19942 and the uncertainty regarding its histogenesis was reflected by the several changes of name, that included agranular CD4+ natural killer cell leukemia,3 blastic natural killer leukemia/lymphoma,4 agranular CD4+CD56+ hematodermic neoplasm5 or tumor.6 In 2001 the World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissue coined the term blastic NKcell lymphoma on the basis of the blastic cytology, and the expression of CD56 in the absence of other lineage specific markers. A relationship to plasmacytoid dendritic cells was hypothesized first by Lucio et al. in 19997 and subsequently confirmed by several studies.5,8-13 The term blastic plasmacytoid dendritic cell neoplasm was introduced in 2008 by the updated WHO classification (4th edition).14 The clinical hallmarks of BPDCN are predominant cutaneous involvement, with subsequent or simultaneous extension to bone marrow and peripheral blood. Systemic dissemination and short survival are characteristic. Morphologically tumor cells show an immature “blastic” appearance; the diagnosis rests upon the demonstration of CD4 and CD56, together with markers more restricted to PDC (such as BDCA-2, CD123, TCL1, CD2AP and BCL11a) and negativity for lymphoid, NK and myeloid lineage- associated antigens.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Facchetti, F., Ungari, M., Marocolo, D., Lonardi, S., & Vermi, W. (2009). Blastic plasmacytoid dendritic cell neoplasm. Hematology Meeting Reports (formerly Haematologica Reports), 3(3). https://doi.org/10.4081/hmr.v3i3.553
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).